Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Evidence of region-wide bat population decline from long-term monitoring and Bayesian occupancy models with empirically informed priors.

Rodhouse TJ, Rodriguez RM, Banner KM, Ormsbee PC, Barnett J, Irvine KM.

Ecol Evol. 2019 Sep 11;9(19):11078-11088. doi: 10.1002/ece3.5612. eCollection 2019 Oct.

2.

Reply.

Hayward KL, Valery PC, Cottrell WN, Irvine KM, Martin JH, Powell EE.

Hepatol Commun. 2019 Jul 10;3(9):1283-1284. doi: 10.1002/hep4.1398. eCollection 2019 Sep. No abstract available.

3.

Analysis of the impact of CSF-1 administration in adult rats using a novel Csf1r-mApple reporter gene.

Irvine KM, Caruso M, Cestari MF, Davis GM, Keshvari S, Sehgal A, Pridans C, Hume DA.

J Leukoc Biol. 2019 Aug 8. doi: 10.1002/JLB.MA0519-149R. [Epub ahead of print]

PMID:
31397014
4.

Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores.

Patel PJ, Cheng JC, Banh X, Gracen L, Radford-Smith D, Hossain F, Horsfall LU, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Stuart KA, Russell AW, Valery PC, Clouston AD, Irvine KM, Bernard A, Powell EE.

Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]

PMID:
31352092
5.

Phenotypic impacts of CSF1R deficiencies in humans and model organisms.

Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM.

J Leukoc Biol. 2019 Jul 22. doi: 10.1002/JLB.MR0519-143R. [Epub ahead of print] Review.

PMID:
31330095
6.

Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation.

Loh Z, Fitzsimmons RL, Reid RC, Ramnath D, Clouston A, Gupta PK, Irvine KM, Powell EE, Schroder K, Stow JL, Sweet MJ, Fairlie DP, Iyer A.

Br J Pharmacol. 2019 Oct;176(19):3775-3790. doi: 10.1111/bph.14768. Epub 2019 Aug 17.

PMID:
31236923
7.

Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells.

Genz B, Coleman MA, Irvine KM, Kutasovic JR, Miranda M, Gratte FD, Tirnitz-Parker JEE, Olynyk JK, Calvopina DA, Weis A, Cloonan N, Robinson H, Hill MM, Al-Ejeh F, Ramm GA.

Sci Rep. 2019 Jun 12;9(1):8541. doi: 10.1038/s41598-019-44865-1.

8.

Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.

Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, Tallis CJ, Stuart KA, Irvine KM, Cottrell WN, Martin JH, Powell EE.

Hepatol Commun. 2019 Mar 18;3(5):620-631. doi: 10.1002/hep4.1334. eCollection 2019 May.

9.

Corrigendum: Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Irvine KM, Ratnasekera I, Powell EE, Hume DA.

Front Immunol. 2019 Apr 9;10:818. doi: 10.3389/fimmu.2019.00818. eCollection 2019.

10.

Wetland drying linked to variations in snowmelt runoff across Grand Teton and Yellowstone national parks.

Ray AM, Sepulveda AJ, Irvine KM, Wilmoth SKC, Thoma DP, Patla DA.

Sci Total Environ. 2019 May 20;666:1188-1197. doi: 10.1016/j.scitotenv.2019.02.296. Epub 2019 Feb 21.

PMID:
30970484
11.

Identifying occupancy model inadequacies: can residuals separately assess detection and presence?

Wright WJ, Irvine KM, Higgs MD.

Ecology. 2019 Jun;100(6):e02703. doi: 10.1002/ecy.2703. Epub 2019 Apr 18.

PMID:
30932179
12.

Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Irvine KM, Ratnasekera I, Powell EE, Hume DA.

Front Immunol. 2019 Feb 25;10:293. doi: 10.3389/fimmu.2019.00293. eCollection 2019. Review. Erratum in: Front Immunol. 2019 Apr 09;10:818.

13.

The Mononuclear Phagocyte System: The Relationship between Monocytes and Macrophages.

Hume DA, Irvine KM, Pridans C.

Trends Immunol. 2019 Feb;40(2):98-112. doi: 10.1016/j.it.2018.11.007. Epub 2018 Dec 19. Review.

PMID:
30579704
14.

ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed in Mammalian Monocyte-Macrophages.

Waddell LA, Lefevre L, Bush SJ, Raper A, Young R, Lisowski ZM, McCulloch MEB, Muriuki C, Sauter KA, Clark EL, Irvine KM, Pridans C, Hope JC, Hume DA.

Front Immunol. 2018 Oct 1;9:2246. doi: 10.3389/fimmu.2018.02246. eCollection 2018.

15.

A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care.

Patel P, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Bernard A, Brown NN, Lampe G, Buck L, Saad N, Russell AW, Valery PC, Irvine KM, Clouston AD, Stuart KA, Rosenberg W, Powell EE.

Hepatol Commun. 2018 Aug 6;2(8):893-905. doi: 10.1002/hep4.1208. eCollection 2018 Aug.

16.

Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.

Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ.

JCI Insight. 2018 Jul 26;3(14). pii: 120274. doi: 10.1172/jci.insight.120274. eCollection 2018 Jul 26.

17.

Improving geographically extensive acoustic survey designs for modeling species occurrence with imperfect detection and misidentification.

Banner KM, Irvine KM, Rodhouse TJ, Wright WJ, Rodriguez RM, Litt AR.

Ecol Evol. 2018 May 20;8(12):6144-6156. doi: 10.1002/ece3.4162. eCollection 2018 Jun.

18.

Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control.

Patel PJ, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Valery PC, Irvine KM, Clouston AD, Stuart KA, Russell AW, Powell EE.

J Diabetes Complications. 2018 Aug;32(8):799-804. doi: 10.1016/j.jdiacomp.2018.05.008. Epub 2018 May 12.

PMID:
29861312
19.

Occupancy modeling species-environment relationships with non-ignorable survey designs.

Irvine KM, Rodhouse TJ, Wright WJ, Olsen AR.

Ecol Appl. 2018 Sep;28(6):1616-1625. doi: 10.1002/eap.1754. Epub 2018 Jul 19.

20.

Macrophage colony-stimulating factor increases hepatic macrophage content, liver growth, and lipid accumulation in neonatal rats.

Pridans C, Sauter KA, Irvine KM, Davis GM, Lefevre L, Raper A, Rojo R, Nirmal AJ, Beard P, Cheeseman M, Hume DA.

Am J Physiol Gastrointest Liver Physiol. 2018 Mar 1;314(3):G388-G398. doi: 10.1152/ajpgi.00343.2017. Epub 2017 Dec 21.

21.

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.

Patel PJ, Smith D, Connor JP, Horsfall LU, Hayward KL, Hossain F, Williams S, Johnson T, Stuart KA, Brown NN, Saad N, Clouston AD, Irvine KM, Russell AW, Valery PC, Powell EE.

Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1.

22.

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis.

Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN.

World J Gastroenterol. 2017 Oct 28;23(40):7321-7331. doi: 10.3748/wjg.v23.i40.7321.

23.

Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.

Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE.

Intern Med J. 2018 Feb;48(2):144-151. doi: 10.1111/imj.13667.

PMID:
29083080
24.

Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis.

Maradana MR, Yekollu SK, Zeng B, Ellis J, Clouston A, Miller G, Talekar M, Bhuyan ZA, Mahadevaiah S, Powell EE, Irvine KM, Thomas R, O'Sullivan BJ.

Metabolism. 2018 Jan;78:80-94. doi: 10.1016/j.metabol.2017.09.002. Epub 2017 Sep 20.

PMID:
28941597
25.

Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management.

Hayward KL, Horsfall LU, Ruffin BJ, Cottrell WN, Chachay VS, Irvine KM, Martin JH, Powell EE, Valery PC.

Intern Med J. 2017 Aug;47(8):952-955. doi: 10.1111/imj.13505.

PMID:
28782215
26.

Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial.

Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU, Patel PJ, Smith DD, Irvine KM, Powell EE, Valery PC.

Trials. 2017 Jul 20;18(1):339. doi: 10.1186/s13063-017-2075-4.

27.

Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.

Patel PJ, Hayward KL, Rudra R, Horsfall LU, Hossain F, Williams S, Johnson T, Brown NN, Saad N, Clouston AD, Stuart KA, Valery PC, Irvine KM, Russell AW, Powell EE.

Medicine (Baltimore). 2017 Jun;96(26):e6761. doi: 10.1097/MD.0000000000006761.

28.

Expression profiling feline peripheral blood monocytes identifies a transcriptional signature associated with type two diabetes mellitus.

O'Leary CA, Sedhom M, Reeve-Johnson M, Mallyon J, Irvine KM.

Vet Immunol Immunopathol. 2017 Apr;186:1-8. doi: 10.1016/j.vetimm.2016.12.011. Epub 2017 Feb 9.

PMID:
28413044
29.

Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers.

Irvine KM, Wockner LF, Hoffmann I, Horsfall LU, Fagan KJ, Bijin V, Lee B, Clouston AD, Lampe G, Connolly JE, Powell EE.

PLoS One. 2016 Nov 18;11(11):e0167001. doi: 10.1371/journal.pone.0167001. eCollection 2016.

30.

CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.

Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, Lukowski S, Baillie GJ, Sweet MJ, Powell EE.

JCI Insight. 2016 Jun 2;1(8):e86914. doi: 10.1172/jci.insight.86914.

31.

Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.

Hayward KL, Valery PC, Cottrell WN, Irvine KM, Horsfall LU, Tallis CJ, Chachay VS, Ruffin BJ, Martin JH, Powell EE.

BMC Gastroenterol. 2016 Sep 13;16:114. doi: 10.1186/s12876-016-0530-4.

32.

A goodness-of-fit test for occupancy models with correlated within-season revisits.

Wright WJ, Irvine KM, Rodhouse TJ.

Ecol Evol. 2016 Jul 5;6(15):5404-15. doi: 10.1002/ece3.2292. eCollection 2016 Aug.

33.

Identifying areas of need relative to liver disease: geographic clustering within a health service district.

El-Atem N, Irvine KM, Valery PC, Wojcik K, Horsfall L, Johnson T, Janda M, McPhail SM, Powell EE.

Aust Health Rev. 2017 Aug;41(4):407-418. doi: 10.1071/AH15225.

PMID:
27509003
34.

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.

Gadd VL, Patel PJ, Jose S, Horsfall L, Powell EE, Irvine KM.

PLoS One. 2016 Jun 16;11(6):e0157771. doi: 10.1371/journal.pone.0157771. eCollection 2016.

35.

Salmonella employs multiple mechanisms to subvert the TLR-inducible zinc-mediated antimicrobial response of human macrophages.

Kapetanovic R, Bokil NJ, Achard ME, Ong CL, Peters KM, Stocks CJ, Phan MD, Monteleone M, Schroder K, Irvine KM, Saunders BM, Walker MJ, Stacey KJ, McEwan AG, Schembri MA, Sweet MJ.

FASEB J. 2016 May;30(5):1901-12. doi: 10.1096/fj.201500061. Epub 2016 Feb 2.

PMID:
26839376
36.

Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease.

El-Atem NA, Wojcik K, Horsfall L, Irvine KM, Johnson T, McPhail SM, Powell EE.

Intern Med J. 2016 Apr;46(4):420-6. doi: 10.1111/imj.13008.

PMID:
26762655
37.

Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model.

Melino M, Gadd VL, Alexander KA, Beattie L, Lineburg KE, Martinez M, Teal B, Le Texier L, Irvine KM, Miller GC, Boyle GM, Hill GR, Clouston AD, Powell EE, MacDonald KP.

Am J Pathol. 2016 Mar;186(3):524-38. doi: 10.1016/j.ajpath.2015.10.029. Epub 2016 Jan 4.

PMID:
26762581
38.

Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury.

Irvine KM, Clouston AD, Gadd VL, Miller GC, Wong WY, Melino M, Maradana MR, MacDonald K, Lang RA, Sweet MJ, Blumenthal A, Powell EE.

Fibrogenesis Tissue Repair. 2015 Oct 15;8:19. doi: 10.1186/s13069-015-0036-7. eCollection 2015.

39.

Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Hayward KL, Powell EE, Irvine KM, Martin JH.

Br J Clin Pharmacol. 2016 Feb;81(2):210-22. doi: 10.1111/bcp.12802. Epub 2015 Dec 25. Review.

40.

Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.

Pang D, Irvine KM, Mehdi AM, Thomas HE, Harris M, Hamilton-Williams EE, Thomas R.

Clin Transl Immunology. 2015 Aug 28;4(8):e41. doi: 10.1038/cti.2015.17. eCollection 2015 Aug.

41.

The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.

Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM, Ungerer JP, Pretorius CJ, Miller GC, Clouston AD, Lampe G, Powell EE.

Liver Int. 2016 Mar;36(3):370-7. doi: 10.1111/liv.12896. Epub 2015 Aug 28.

PMID:
26104018
42.

Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.

Fagan KJ, Rogers GB, Melino M, Arthur DM, Costello ME, Morrison M, Powell EE, Irvine KM.

PLoS One. 2015 Mar 17;10(3):e0120642. doi: 10.1371/journal.pone.0120642. eCollection 2015.

43.

Response to ELF cut-off points: aetiology is also a relevant factor.

Powell EE, Irvine KM, Fagan KJ, Ballard E, O'Rourke P.

Liver Int. 2015 Jul;35(7):1921. doi: 10.1111/liv.12822. Epub 2015 Mar 27. No abstract available.

PMID:
25762021
44.

Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Irvine KM, Skoien R, Bokil NJ, Melino M, Thomas GP, Loo D, Gabrielli B, Hill MM, Sweet MJ, Clouston AD, Powell EE.

World J Gastroenterol. 2014 Dec 21;20(47):17851-62. doi: 10.3748/wjg.v20.i47.17851.

45.

ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity.

Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K, Fletcher LM, Tate J, Melino M, Nusrat S, Miller GC, Clouston AD, Ballard E, O'Rourke P, Lampe G, Ungerer JP, Powell EE.

Liver Int. 2015 Jun;35(6):1673-81. doi: 10.1111/liv.12760. Epub 2015 Jan 20.

PMID:
25495373
46.

Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?

Fagan KJ, Zhao EY, Horsfall LU, Ruffin BJ, Kruger MS, McPhail SM, O'Rourke P, Ballard E, Irvine KM, Powell EE.

Intern Med J. 2014 Sep;44(9):865-72. doi: 10.1111/imj.12491.

PMID:
24893971
47.

Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers.

Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, O'Rourke P, Martin J, Scott I, Pretorius CJ, Ungerer JP, Powell EE.

BMC Gastroenterol. 2014 May 22;14:97. doi: 10.1186/1471-230X-14-97.

48.

Recombinant Wnt3a and Wnt5a elicit macrophage cytokine production and tolerization to microbial stimulation via Toll-like receptor 4.

Yu CH, Nguyen TT, Irvine KM, Sweet MJ, Frazer IH, Blumenthal A.

Eur J Immunol. 2014 May;44(5):1480-90. doi: 10.1002/eji.201343959. Epub 2014 Mar 7.

49.

Evaluation of a combined macrophyte-epiphyte bioassay for assessing nutrient enrichment in the Portneuf River, Idaho, USA.

Ray AM, Mebane CA, Raben F, Irvine KM, Marcarelli AM.

Environ Monit Assess. 2014 Jul;186(7):4081-96. doi: 10.1007/s10661-014-3682-0. Epub 2014 Feb 20.

PMID:
24549944
50.

BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin.

Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson LA, Clouston AD, Jonsson JR, O'Rourke P, Martin J, Pretorius CJ, Ungerer JP, Powell EE.

Alcohol Clin Exp Res. 2013 Oct;37(10):1771-8. doi: 10.1111/acer.12143. Epub 2013 Jul 22.

PMID:
23875541

Supplemental Content

Loading ...
Support Center